|
New Breast Cancer Drugs Gets The Nod
22/Sep/2006: The Government’s health watchdog has given its nod to new breast cancer drugs.
The National Institute for Health and Clinical Excellence (NICE) has issued a final draft appraisal on the three breakthrough drugs that slows down aromatase in postmenopausal women who are diagnosed with early stage of breast cancer.
The drugs Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) are said to be effective in reducing the spread of tumors which may occur after surgery.
These drugs which halt the natural production of estrogen (the cause of many breast cancers) will be extremely beneficial for women who live with hormone receptor positive for early breast cancer.
The 2004 study conducted by the Cancer Research UK reported recently that patients, who replaced tamoxifen with Aromasin midway through treatment, experienced reduced risk of recurrence of the disease by one third.
A study by the Intergroup Exemestane showed that patients who are on Aromasin reduce the risk of death by 17% and patients who took Arimidex right after surgery showed a further 26% reduction in cancer recurrence in addition to the 50% by tamoxifen.
These positive effects have prompted Government to encourage doctors to start prescribing these drugs instead of waiting for NICE to complete guidance stages.
Copyright Clipp.org
|
 Eco
Features
Eco
Guides
Health
& Lifestyle
Mail
This Page
Link
To Us
Bookmark
Archives
 Recent Articles
Cows contribute to global warming!
New treatment for acne scars
Researchers develop a novel treatment for dementia
Ovulation influence women’s lifestyle
Fighting global warming could benefit world economies
|
